Send to:

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2014 Jul;96(1):15-7. doi: 10.1038/clpt.2014.44.

Patients benefit from genetics-guided coumarin anticoagulant therapy.

Author information

  • 1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
  • 2Institute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, UK.
  • 3Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
  • 4Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden.
  • 5The Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Erratum in

  • Clin Pharmacol Ther. 2014 Sep;96(3):397. Manolopoulos, V G [corrected to Manolopoulous, V G].


Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk